{"id":"https://genegraph.clinicalgenome.org/r/7dd312fd-4647-4bb8-8042-c314357dba66v2.0","type":"EvidenceStrengthAssertion","dc:description":"*ATP6AP1* was first reported in relation to ATP6AP1-CDG (also known as Immunodeficiency 47, MIM#300972) in 2016 (Jansen EJ, et al., 2016, PMID: 27231034). ATP6AP1 codes for an accessory subunit of a V‐ATPase, which normally pumps cytosolic protons into the lumen of endocytic and secretory organelles and thus maintains the acidic pH to ensure their correct function.\n\nHemizygous males typically present with hepatic dysfunction (ranging from increased transaminases to cholestasis, liver cirrhosis, and end stage liver failure), and immunodeficiency (frequent infections, leukopenia and low immunoglobulin levels). Hematological and neurological features are also common. Patients exhibit abnormal N-glycosylation and often abnormal 0-glycosylation patterns. Other features reported include sensorineural hearing loss, renal dysfunction, pancreatic insufficiency, and lipid and amino acid profile abnormalities, low serum copper and ceruloplasmin. \n\nEleven missense and one nonsense variant have been reported in 19 male probands, and 12 additional male family members, from 10 publications, were curated (Jansen et al, 2016, PMID: 27231034; Witters et al, 2018, PMID: 29192153; Dimitrov et al, 2018, PMID: 29396028; Tvina et al, 2020; PMID: 32058063, Ondruskova et al, 2020, PMID: 32216104; Yang et al, 2021, PMID: 34621841; Barua et al, 2022, PMID: 35732497; Alharbi et al, 2023, PMID: 35732497; Dang et al, 2023, PMID: 36719165; Semenova et al, 2023; PMID: 37108612). The mechanism of pathogenicity appears to be loss of function. All genotyped patients were hemizygous males; where the inheritance pattern is known 6 probands had a de novo variant and 13 had a maternally inherited variant. The ATP6AP1:c.1036G>A (p.Glu346Lys) variant is a recurrent de novo variant, and is inherited in some cases (Jansen et al, 2016, PMID: 27231034; Yang et al, 2021, PMID: 34621841; Alharbi et al, 2023, PMID: 35732497; Dang et al, 2023, PMID: 36719165).\n\nThis gene-disease association is supported by experimental evidence showing that the function of ATP6AP1 is consistent with disease phenotypes, and that ATP6AP1 interacts with other proteins associated with CDG (Supek et al, 1994, PMID: 7929063; Wang et al, 2020, PMID: 33065002; Huttlin et al, 2017, PMID: 28514442). Specifically, ATP6AP1 (also known as Ac45) has been shown to act as a central hub for bringing the subunits of v-ATPase together for assembly into the complex (PMID: 33065002). Other genes encoding subunits of v-ATPase have been associated with CDG and are known to impact assembly or structure of the complex (Van Damme). A knock-out and conditional knock-out mouse model result in embryonic lethality (Schoonderwoert et al, 2002 PMID: 11989824; Qin et al, 2011, PMID: 22087256). In summary, there is definitive evidence to support the relationship between *ATP6AP1* and ATP6AP1-CDG. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen CDG GCEP on the meeting date May 15, 2024 (SOP v10).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/7dd312fd-4647-4bb8-8042-c314357dba66","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:sopChange"},"contributions":[{"agent":"https://genegraph.clinicalgenome.org/agent/10080","role":"SecondaryContributor"},{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2024-12-10T19:57:42.176Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2024-05-15T16:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationTiming","RecurationNewEvidence","ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/93cd9af6-c312-44b4-b069-11a24c590d84","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/93cd9af6-c312-44b4-b069-11a24c590d84_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/3a4bd625-6d92-4656-a821-77d4821722ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.294C>A (p.Ser98Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415188894"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f8426a0f-8d09-4e04-94ff-31933b8c7086","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8426a0f-8d09-4e04-94ff-31933b8c7086_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","allele":{"id":"https://genegraph.clinicalgenome.org/r/92627fac-82f5-4451-a71c-c52973f4348a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.431T>C (p.Leu144Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581575"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4d118e20-24ae-4657-9d8c-aab98ff3c945","type":"EvidenceLine","dc:description":"Two affected brothers of the Druze family harbor the Glu364Lys variant which was previously included in Family 4.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d118e20-24ae-4657-9d8c-aab98ff3c945_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.1036G>A (p.Glu346Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581576"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/4d118e20-24ae-4657-9d8c-aab98ff3c945_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/487e7071-ddd0-4b84-a03a-6cfbc42ed875","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/487e7071-ddd0-4b84-a03a-6cfbc42ed875_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/f3430e9d-8ec0-4e72-b426-0cd054a17390","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.25C>T (p.Arg9Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415187310"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2cea8679-2d6e-4f13-b60e-2c0cf1762525","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2cea8679-2d6e-4f13-b60e-2c0cf1762525_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","allele":{"id":"https://genegraph.clinicalgenome.org/r/2d89b1fd-622a-43c6-a3cf-5f5cd178d2da","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.938A>G (p.Tyr313Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581577"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/2cea8679-2d6e-4f13-b60e-2c0cf1762525_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17537b1a-42f3-4d1e-8f5b-cdebb30a7541_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32216104","rdfs:label":"Ondruskova_2020: Czech Family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/17537b1a-42f3-4d1e-8f5b-cdebb30a7541","type":"Family","rdfs:label":"Ondruskova_2020: Czech Family","member":{"id":"https://genegraph.clinicalgenome.org/r/d19e0bca-7235-4303-917d-8f828f1b9a81","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32216104","rdfs:label":"Ondruskova_2020: P1","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f9405ec4-c8c2-4f01-8986-469ec229074d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.221T>C (p.Leu74Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/915879"}},"detectionMethod":"trio WES in P1, confirmed by Sanger in P2","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001522","obo:HP_0001399","obo:HP_0011967","obo:HP_0012347","obo:HP_0012358","obo:HP_0001396","obo:HP_0000973","obo:HP_0001433","obo:HP_0006579","obo:HP_0001397","obo:HP_0002910"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f5f4b5c5-9ed2-4757-8a6e-de5207bb7e0f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32216104","allele":{"id":"https://genegraph.clinicalgenome.org/r/f9405ec4-c8c2-4f01-8986-469ec229074d"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0011967","obo:HP_0012347","obo:HP_0001396","obo:HP_0000973","obo:HP_0001433","obo:HP_0001522","obo:HP_0001397","obo:HP_0001399","obo:HP_0006579","obo:HP_0002910","obo:HP_0012358"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d19e0bca-7235-4303-917d-8f828f1b9a81"}},{"id":"https://genegraph.clinicalgenome.org/r/a72d48bf-7732-4c6d-b67f-d73ccf797448_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32058063","rdfs:label":"Tvina_2020: Brothers","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/a72d48bf-7732-4c6d-b67f-d73ccf797448","type":"Family","rdfs:label":"Tvina_2020: Brothers","member":{"id":"https://genegraph.clinicalgenome.org/r/ecd2d1a2-a956-493c-8810-95ac67485a8f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32058063","rdfs:label":"Tvina_2020: Older Brother","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8d4a1b99-608e-4099-9218-1ef78e74660f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.932T>A (p.Leu311Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/804234"}},"detectionMethod":"Genome sequencing in older brother, unspecified methods in younger brother.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0002910","obo:HP_0100512","obo:HP_0000952","obo:HP_0006577","obo:HP_0001744","obo:HP_0004313"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6551d086-72bf-495d-b893-db72fea0fff2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32058063","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d4a1b99-608e-4099-9218-1ef78e74660f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000952","obo:HP_0002910"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/ecd2d1a2-a956-493c-8810-95ac67485a8f"}},{"id":"https://genegraph.clinicalgenome.org/r/f35cc22f-41aa-42db-a5eb-83f7be3d1635_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: Family 5","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/f35cc22f-41aa-42db-a5eb-83f7be3d1635","type":"Family","rdfs:label":"Jansen_2016: Family 5","member":{"id":"https://genegraph.clinicalgenome.org/r/3af9bd39-a36a-41ec-8b5e-a9c409f76c74","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: P 5.2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"neurologic symptoms, IgM 7.4 mg/dl, IgG <6.3 mg/dl","phenotypes":["obo:HP_0011967","obo:HP_0001410","obo:HP_0012358","obo:HP_0002240","obo:HP_0001882","obo:HP_0012347","obo:HP_0002719","obo:HP_0002910","obo:HP_0001744"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2364333f-a929-45e3-9d59-c1df9b4a3232_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"neurologic symptoms","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001882","obo:HP_0002719","obo:HP_0001410","obo:HP_0002240","obo:HP_0002910","obo:HP_0012347","obo:HP_0011967"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/3af9bd39-a36a-41ec-8b5e-a9c409f76c74"}},{"id":"https://genegraph.clinicalgenome.org/r/c61e2b92-dc60-43ee-bb3c-8644e8f18f34_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: Family 3","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/c61e2b92-dc60-43ee-bb3c-8644e8f18f34","type":"Family","rdfs:label":"Jansen_2016: Family 3","member":{"id":"https://genegraph.clinicalgenome.org/r/da8b28d6-f75b-462f-884d-2a53b8e20210","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: P 3.1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"neurologic symptoms, IgG 521 mg/dl","phenotypes":["obo:HP_0001394","obo:HP_0001397","obo:HP_0001744","obo:HP_0002240","obo:HP_0011967","obo:HP_0012358","obo:HP_0002910","obo:HP_0001882","obo:HP_0012347","obo:HP_0000403","obo:HP_0002719"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4d118e20-24ae-4657-9d8c-aab98ff3c945_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"neurologic symptoms","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0012347","obo:HP_0001394","obo:HP_0001882","obo:HP_0002719","obo:HP_0001397","obo:HP_0002240","obo:HP_0001744","obo:HP_0002910","obo:HP_0011967"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/da8b28d6-f75b-462f-884d-2a53b8e20210"}},{"id":"https://genegraph.clinicalgenome.org/r/1fb9726a-e1b8-4ac3-898c-88256009e332_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: Family 4","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/1fb9726a-e1b8-4ac3-898c-88256009e332","type":"Family","rdfs:label":"Jansen_2016: Family 4","member":{"id":"https://genegraph.clinicalgenome.org/r/405b5dcd-68c2-4dcc-83cb-689ac80df185","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: P 4.1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"neurologic symptoms, IgG 155 mg/dl, IgM 67 mg/dl, IgG 54 mg/dl","phenotypes":["obo:HP_0011967","obo:HP_0001882","obo:HP_0012347","obo:HP_0001413","obo:HP_0004313","obo:HP_0006579","obo:HP_0012358","obo:HP_0002719","obo:HP_0001433","obo:HP_0002910","obo:HP_0000540"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/86200eb7-3c19-493d-a36e-4208aaa45f8f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"neurologic symptoms","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002719","obo:HP_0004313","obo:HP_0012347","obo:HP_0011967","obo:HP_0012358","obo:HP_0001433","obo:HP_0006579","obo:HP_0001882","obo:HP_0002910","obo:HP_0001413"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/405b5dcd-68c2-4dcc-83cb-689ac80df185"}},{"id":"https://genegraph.clinicalgenome.org/r/9dfe66ae-505b-4f49-9101-8389e8230a1c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","rdfs:label":"Alharbi_2023: Family 6","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/9dfe66ae-505b-4f49-9101-8389e8230a1c","type":"Family","rdfs:label":"Alharbi_2023: Family 6","member":{"id":"https://genegraph.clinicalgenome.org/r/56c18a8b-95ce-4036-858c-ff35b5785ef8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","rdfs:label":"Alharbi_2023: P6","allele":{"id":"https://genegraph.clinicalgenome.org/r/e0f2dd90-8b44-4b77-8d56-8df2ef44c1f2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.401C>T (p.Pro134Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415189364"}},"detectionMethod":"Genotyping method was not provided.","phenotypeFreeText":"Recurrent bacterial infections pre-liver transplant. Liver transplant at 9 months of age.\nMildly low factors XI, X, IX, V and II.\nCutis laxa -  anterior chest and abdomen.","phenotypes":["obo:HP_0001738","obo:HP_0001394","obo:HP_0001433","obo:HP_0001903","obo:HP_0002910","obo:HP_0001399","obo:HP_0000293","obo:HP_0001396"],"previousTesting":true,"previousTestingDescription":"Normal copper, low ceruloplasmin\nSee Table 2. Significant N-glycosylation abnormalities in fractionated plasma glycoproteins: Immunoglobulin G, transferrin and the remaining glycoprotein fraction. ","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9a85c889-0867-478f-9bb1-1af8d57cd252_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/e0f2dd90-8b44-4b77-8d56-8df2ef44c1f2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/56c18a8b-95ce-4036-858c-ff35b5785ef8"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/b6b107e9-1e55-4f7e-81f1-8f63166ddf7d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: Family 1","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/b6b107e9-1e55-4f7e-81f1-8f63166ddf7d","type":"Family","rdfs:label":"Jansen_2016: Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/f58024b5-1a68-45d5-a89c-8bdc15c5fffc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","rdfs:label":"Jansen_2016: P 1.1 (III:3)","ageType":"AgeAtReport","ageUnit":"Years","ageValue":20,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cd49a215-8801-4e0d-8b64-1bb53377d02f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.1284G>A (p.Met428Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581574"}},"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"IgG 620 mg/dl","phenotypes":["obo:HP_0000407","obo:HP_0000540","obo:HP_0006579","obo:HP_0012347","obo:HP_0002910","obo:HP_0011967","obo:HP_0002240","obo:HP_0001882","obo:HP_0004313","obo:HP_0002719","obo:HP_0012358"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1a7d3f0e-1488-47f8-a6bb-83c23a261b88_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27231034","allele":{"id":"https://genegraph.clinicalgenome.org/r/cd49a215-8801-4e0d-8b64-1bb53377d02f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0002719","obo:HP_0001882","obo:HP_0004313","obo:HP_0012358","obo:HP_0012347","obo:HP_0000540","obo:HP_0000407","obo:HP_0002910"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f58024b5-1a68-45d5-a89c-8bdc15c5fffc"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1a7d3f0e-1488-47f8-a6bb-83c23a261b88","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a7d3f0e-1488-47f8-a6bb-83c23a261b88_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1a7d3f0e-1488-47f8-a6bb-83c23a261b88_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Met428Ile was indistinguishable from wild-type in restoring V-ATPase-dependent growth in Voa1 mutant yeast","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f42978c4-baaa-4e4c-ba88-3d37ec956872","type":"EvidenceLine","dc:description":"Recurrent de novo variant but score reduced to avoid overcounting functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f42978c4-baaa-4e4c-ba88-3d37ec956872_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f42978c4-baaa-4e4c-ba88-3d37ec956872_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1 (PMID: 27231034)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/0911aa70-14d7-44d9-9937-f8e4ae39b43f","type":"EvidenceLine","dc:description":"Previously reported by Jansen et al in another patient.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0911aa70-14d7-44d9-9937-f8e4ae39b43f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37108612","allele":{"id":"https://genegraph.clinicalgenome.org/r/2d89b1fd-622a-43c6-a3cf-5f5cd178d2da"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/0911aa70-14d7-44d9-9937-f8e4ae39b43f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast (PMID: 27231034).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/6551d086-72bf-495d-b893-db72fea0fff2","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6551d086-72bf-495d-b893-db72fea0fff2_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2364333f-a929-45e3-9d59-c1df9b4a3232","type":"EvidenceLine","dc:description":"Two affected brothers of the Tunisian family harbor the Glu364Lys variant which was previously included in Families 3 and 4.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2364333f-a929-45e3-9d59-c1df9b4a3232_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2364333f-a929-45e3-9d59-c1df9b4a3232_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/e82e0163-a823-4df7-937b-c120727b2143","type":"EvidenceLine","dc:description":"Recurrent de novo variant but score reduced to avoid overcounting functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e82e0163-a823-4df7-937b-c120727b2143_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e82e0163-a823-4df7-937b-c120727b2143_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1 (PMID: 27231034)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/6f58f2ce-b1e4-415c-abe9-847632646326","type":"EvidenceLine","dc:description":"Recurrent de novo variant but score reduced to avoid overcounting functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f58f2ce-b1e4-415c-abe9-847632646326_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6f58f2ce-b1e4-415c-abe9-847632646326_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1 (PMID: 27231034)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/74a62643-748b-4696-a1d3-c68c905e6403","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/74a62643-748b-4696-a1d3-c68c905e6403_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29192153","allele":{"id":"https://genegraph.clinicalgenome.org/r/73f30202-1adf-4f07-8516-b6b0f317764b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.649T>A (p.Tyr217Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415190926"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/86200eb7-3c19-493d-a36e-4208aaa45f8f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86200eb7-3c19-493d-a36e-4208aaa45f8f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/86200eb7-3c19-493d-a36e-4208aaa45f8f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f5f4b5c5-9ed2-4757-8a6e-de5207bb7e0f","type":"EvidenceLine","dc:description":"A significantly decreased amount of the full‐length 62‐kDa form was observed in his frontal cortex and liver, however in the patient's fibroblasts, there was, in addition to a slight increase in the protein's amount, altered gel mobility—a shift to a higher molecular weight.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f5f4b5c5-9ed2-4757-8a6e-de5207bb7e0f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f5f4b5c5-9ed2-4757-8a6e-de5207bb7e0f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Twenty four‐hour transient transfection of the control's and patient's fibroblasts to produce FLAG‐tagged ATP6AP1wt and ATP6AP1L74P demonstrated the altered gel mobility of ATP6AP1L74P to be mutation‐induced and independent on the genetic background, while further experiments indicated that the attachment of (an) extra N‐glycan(s) on the mutant protein is an early event in ATP6AP1 biosynthesis.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d4f68721-b433-48eb-9c40-a198126e7934","type":"EvidenceLine","dc:description":"On Western blot analysis, ATP6AP1 of the patient was reduced to 48.9% ± 1.9%. qRT-PCR studies revealed that the quantity of the patient's ATP6AP1 mRNA was reduced to 57% ± 1%.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d4f68721-b433-48eb-9c40-a198126e7934_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29396028","allele":{"id":"https://genegraph.clinicalgenome.org/r/6d8c50d9-ce57-4be0-8541-07814277cec8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.542T>G (p.Leu181Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415190062"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/9a85c889-0867-478f-9bb1-1af8d57cd252","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a85c889-0867-478f-9bb1-1af8d57cd252_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/857a18f4-ccb6-4807-ae45-6ddc7926cd06","type":"EvidenceLine","dc:description":"Recurrent de novo variant but down scored to avoid overcounting functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/857a18f4-ccb6-4807-ae45-6ddc7926cd06_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34621841","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/857a18f4-ccb6-4807-ae45-6ddc7926cd06_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1 (PMID: 27231034).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/87809dac-1e93-47e8-b8e2-ecc3427532c4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87809dac-1e93-47e8-b8e2-ecc3427532c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36651831","allele":{"id":"https://genegraph.clinicalgenome.org/r/18ae301e-0b51-4103-8cc8-8fd6b70e8c8c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001183.6(ATP6AP1):c.230_232del (p.Tyr77del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573159443"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f23b1dc8-6062-4e43-85ad-e8de9b96a045","type":"EvidenceLine","dc:description":"A patient with this variant has already been scored.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f23b1dc8-6062-4e43-85ad-e8de9b96a045_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36719165","allele":{"id":"https://genegraph.clinicalgenome.org/r/afc7647b-b55b-4c16-91d8-2c93582e6379"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f23b1dc8-6062-4e43-85ad-e8de9b96a045_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Wild-type Ac45, but not this variant, restored V-ATPase-dependent growth in Voa1 mutant yeast. The Glu364Lys variant exhibited reduced growth nearing that of yeast having no Voa1 ( PMID: 27231034).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9.35},{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2aa41dc5-b929-4e0d-9865-1101d739a05e","type":"EvidenceLine","dc:description":"Score increased based on the number of genes encoding v-ATPase subunits that are associated with CDG.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/49a5d110-ff2c-4947-915f-1290bfe4324d","type":"Finding","dc:description":"The authors used affinity purification-mass spectrometry methodology to elucidate protein interaction networks and co-complexes. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28514442","rdfs:label":"V-ATPase interactions","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/13fec91b-1ede-401e-a069-ca2b0d08ff7f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8902695-d172-426a-888e-2d00d5e9784a","type":"Finding","dc:description":"The authors report cryoelectron microscopy structures of human V-ATPase, affinity purified from HEK293F cells, in three rotational states at up to 2.9-A˚ resolution. They found that ATP6AP1 interacts with multiple subunits as well as c-ring lipids in the Vo complex, therefore acting as a central hub for bringing subunits together for assembly. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33065002","rdfs:label":"V-ATPase accessory protein","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0186bb65-1b25-4dc9-b932-681eb2d88ef6","type":"EvidenceLine","dc:description":"The authors searched for accessory proteins in purified preparations of V-ATPase from bovine chromaffin granules. A protein was identified at 45 kDA and cloned. Using a specific antibody for Ac45 they demonstrated that it copurified with the V-ATPase.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4d7f62a-49c7-4426-b2ad-9af307bb31a9","type":"Finding","dc:description":"V‐ATPase pumps cytosolic protons into the lumen of endocytic and secretory organelles and thus maintains the acidic pH to ensure their correct function (including Golgi glycosylation), as well as serves to acidify the extracellular space in specific cells. Mutations in four more genes encoding different V‐ATPase subunits (ATP6V0A2, ATP6V1A, ATP6V1E1, and ATP6AP2) have been found to underlie a glycosylation disorder in humans (reviewed in PMID: 19171192).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7929063","rdfs:label":"V-ATPase accessory","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c6bfce2b-c20c-40f9-b2f5-d81f76a328f7_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2a0d981-4553-4a42-bf9d-69ef9d2935aa","type":"EvidenceLine","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43a97778-5a3c-4bd5-9ada-252a9a41336a","type":"Finding","dc:description":"To assess the function of Ac45, the authors disrupted its gene by gene targeting in male mouse embryonic stem cells. Of 267 blastocysts injected with ES cells derived from clones containing the targeted gene (i.e. ATP6AP1 KO), only 16 embryos survived to birth. All were female, and all but one were considered to be wild type, based on fur color; one female was believed to be a chimera and died at 6 weeks of age. The authors concluded that the injected ES cells affected the normal development of  the blastocyst. This prenatal lethality with complete penetrance in males does not allow for the relevance to the clinical features of ATP6AP1-CDG to be assessed. However, data from gnomAD v2.1.1. indicated that there are no loss of functional variants (pLI score = 0.99) indicating high constraint for this gene and suggesting lethality for males with complete LOF variants.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11989824","rdfs:label":"ATP6AP1 KO mouse - embryonic lethality","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/525c5f67-200a-4c8e-a2ae-d921f58d051e","type":"EvidenceLine","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e06b6b6-82e1-4d3e-857b-d6f6c6f87e66","type":"Finding","dc:description":"siRNA suppression of ATP6AP1 (a.k.a. Ac45) in mouse osteoclasts was shown to affect the function of V-ATPase, causing impaired intracellular acidification and endocytosis. An attempt to generate conditional osteoclast ATP6AP1-KO mice resulted in embryonic lethality, with impaired CNS development.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22087256","rdfs:label":"ATP6AP1 (a.k.a. Ac45) knockdown ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":9489,"specifiedBy":"GeneValidityCriteria11","strengthScore":11.35,"subject":{"id":"https://genegraph.clinicalgenome.org/r/ZRXB-IWnx9E","type":"GeneValidityProposition","disease":"obo:MONDO_0005501","gene":"hgnc:868","modeOfInheritance":"obo:HP_0001417"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c6bfce2b-c20c-40f9-b2f5-d81f76a328f7-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}